Literature DB >> 11444200

k-ras mutation may be an early event in mucinous ovarian tumorigenesis.

A P Garrett1, K R Lee, C R Colitti, M G Muto, R S Berkowitz, S C Mok.   

Abstract

We explored the possible pathogenetic pathway for mucinous ovarian tumorigenesis by examining the k-ras mutational patterns in ovarian mucinous tumors (OMTs) with benign, borderline, and invasive epithelium in which the different types of mucinous epithelium are in close proximity. Sixteen patients with ovarian mucinous borderline tumors (OMBTs) and 4 patients with grade 1 ovarian mucinous adenocarcinomas (OMCs) were selected for the presence of a single histologic section which contained a clear "transition" zone from benign mucinous epithelium to borderline mucinous epithelium, and in four cases, to invasive epithelium. A PixCell II Laser Capture Microscope was used to microdissect and retrieve benign, borderline, and invasive epithelium separately from the 20 OMTs. Normal ovarian stroma from the same histologic section in each case was also microdissected and retrieved for use as a control. k-ras mutations were detected in these samples by PCR-SSCP analysis followed by direct PCR cycle sequencing. k-ras mutations were found in 8/16 (50%) of the OMBTs and 2/4 (50%) of the grade 1 OMCs. In 6 of these 10 cases (4 in OMBTs, 2 in grade 1 OMCs), the same k-ras mutation was found in both the benign and borderline (and invasive) regions. In 3 cases in which k-ras mutations were identified, the mutation was found in either the benign or borderline tissue samples alone, and in one case, two distinct mutations were found. No k-ras mutations were identified in the normal ovarian stroma. The presence of a k-ras mutation in adjacent benign and borderline regions of a single OMT may suggest a progression in the development of OMTs from benign to borderline and grade 1 OMCs. k-ras mutations, when they occur, are likely early genetic changes but may not alone be sufficient for malignant transformation of ovarian epithelium.

Entities:  

Mesh:

Year:  2001        PMID: 11444200     DOI: 10.1097/00004347-200107000-00007

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  16 in total

Review 1.  Classification of ovarian cancer: a genomic analysis.

Authors:  Michael P Stany; Tomas Bonome; Fred Wamunyokoli; Kristen Zorn; Laurent Ozbun; Dong-Choon Park; Ke Hao; Jeff Boyd; Anil K Sood; David M Gershenson; Ross S Berkowitz; Samuel C Mok; Michael J Birrer
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.

Authors:  Shipeng Gong; Yongning Chen; Fanliang Meng; Yadi Zhang; Chanyuan Li; Guangping Zhang; Wu Huan; Fei Wu
Journal:  Cell Prolif       Date:  2018-08-02       Impact factor: 6.831

3.  Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.

Authors:  Emiko Niiro; Sachiko Morioka; Kana Iwai; Yuki Yamada; Kenji Ogawa; Naoki Kawahara; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2018-01-17

Review 4.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

5.  REDD1 and p-AKT over-expression may predict poor prognosis in ovarian cancer.

Authors:  Wei Jia; Bin Chang; Lili Sun; Huimin Zhu; Lijuan Pang; Lin Tao; Hong Zou; Jinze Du; Yuling Dong; Yan Qi; Jinfang Jiang; Weihua Liang; Feng Li; Xia Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

6.  Molecular characterization of 103 ovarian serous and mucinous tumors.

Authors:  Ildikó Vereczkey; Orsolya Serester; Judit Dobos; Mónika Gallai; Orsolya Szakács; Zoltán Szentirmay; Erika Tóth
Journal:  Pathol Oncol Res       Date:  2010-12-07       Impact factor: 3.201

Review 7.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.

Authors:  Ignacio Romero; Robert C Bast
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

Review 8.  [Mucinous ovarian neoplasms. Prognostically mostly excellent, infrequently a wolf in sheep's clothing].

Authors:  S Lax; A Staebler
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

9.  Mitotic arrest deficiency 2 induces carcinogenesis in mucinous ovarian tumors.

Authors:  Yusuke Nakano; Toshiyuki Sumi; Masanari Morishita; Takeshi Fukuda; Hiroyuki Nobeyama; Hiroyuki Yoshida; Yoshinari Matsumoto; Tomoyo Yasui; Osamu Ishiko
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

Review 10.  Early events in ovarian oncogenesis.

Authors:  Dusica Cvetkovic
Journal:  Reprod Biol Endocrinol       Date:  2003-10-07       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.